期刊
ADVANCES IN THERAPY
卷 29, 期 2, 页码 79-98出版社
SPRINGER
DOI: 10.1007/s12325-011-0100-7
关键词
arachidonic acid; cyclooxygenase; flavocoxid; leukotrienes; licofelone; 5-lipoxygenase; NSAIDs; prostacyclin; prostaglandin; tepoxalin; thromboxane
Cyclooxygenase (COX)-1, COX-2, and 5-lipoxygenase (5-LOX) enzymes produce effectors of pain and inflammation in osteoarthritis (OA) and many other diseases. All three enzymes play a key role in the metabolism of arachidonic acid (AA) to inflammatory fatty acids, which contribute to the deterioration of cartilage. AA is derived from both phospholipase A(2)(PLA(2)) conversion of cell membrane phospholipids and dietary consumption of omega-6 fatty acids. Nonsteroidal antiinflammatory drugs (NSAIDs) inhibit the COX enzymes, but show no anti-5-LOX activity to prevent the formation of leukotrienes (LTs). Cysteinyl LTs, such as LTC4, LTD4, LTE4, and leukoattractive LTB4 accumulate in several organs of mammals in response to NSAID consumption. Elevated 5-LOX-mediated AA metabolism may contribute to the side-effect profile observed for NSAIDs in OA. Current therapeutics under development, so-called dual inhibitors of COX and 5-LOX, show improved side-effect profiles and may represent a new option in the management of OA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据